Orris

Cilostazol mode of action

Reading File
Finding Sources
Searching PubMed

cilostazol mechanism of action PDE3 inhibitor

Reading File
Reading File
Reading File
Searching Images

cilostazol mechanism of action cAMP PDE3 platelet aggregation vasodilation diagram

Here is a complete breakdown of cilostazol's mode of action, drawn from multiple authoritative pharmacology textbooks.

Cilostazol - Mode of Action

Chemical Class

Cilostazol is a quinolinone derivative and a selective phosphodiesterase type III (PDE3) inhibitor.

Core Mechanism

Step 1 - PDE3 Inhibition Cilostazol and its active metabolites selectively inhibit PDE3, the enzyme responsible for degrading cyclic adenosine monophosphate (cAMP) inside cells. By blocking PDE3, cilostazol prevents the breakdown of cAMP, causing intracellular cAMP to accumulate.
Step 2 - Effects of raised cAMP in platelets In platelets, elevated cAMP activates protein kinase A (PKA), which phosphorylates and inhibits downstream signaling pathways that normally lead to platelet activation. The net result is:
  • Inhibition of platelet aggregation (ADP- and arachidonic acid-mediated pathways are suppressed)
  • When combined with aspirin, cilostazol inhibits ADP-induced aggregation by about 30% more than cilostazol alone
Step 3 - Effects of raised cAMP in vascular smooth muscle In vascular smooth muscle cells, elevated cAMP promotes vasodilation of arterioles (particularly in the limbs), improving blood flow to ischemic muscle.

Summary Table

TargetEffectOutcome
PDE3 in plateletscAMP accumulatesPlatelet aggregation inhibited
PDE3 in vascular smooth musclecAMP accumulatesArteriolar vasodilation
CYP3A4 / CYP2C19 (metabolism)Hepatic metabolismMultiple drug interactions

Pharmacokinetics

  • Oral bioavailability, extensively metabolized in the liver by CYP3A4 and CYP2C19
  • Cilostazol and its active metabolites have elimination half-lives of approximately 11-13 hours
  • Primary route of elimination: urine (~75% of clearance)

Clinical Indications

  • Intermittent claudication (peripheral artery disease) - the only FDA-approved indication
  • Reduces symptoms by improving walking distance (by 30-50% in some patients)
  • Used in stroke prevention in some Asian guidelines (supported by a 2024 systematic review on cognitive effects)

Key Adverse Effects

  • Headache (most common)
  • Palpitations, ventricular tachycardia (non-sustained)
  • GI effects: diarrhea, dyspepsia, abnormal stools, abdominal pain
  • Rarely: thrombocytopenia, leukopenia

Key Contraindication

Heart failure of any severity - Cilostazol is in the same drug class as milrinone (another PDE3 inhibitor), which was associated with increased sudden cardiac death when used orally in heart failure patients. While it is not definitively proven that cilostazol itself increases mortality in heart failure, it carries this class contraindication.

Key Drug Interactions

Because cilostazol is metabolized by CYP3A4 and CYP2C19, strong inhibitors of these enzymes (e.g., omeprazole, fluconazole, diltiazem) can significantly raise cilostazol plasma levels, requiring dose reduction.
Sources:
  • Lippincott Illustrated Reviews: Pharmacology, p. 447
  • Goldman-Cecil Medicine, Ch. on Antiplatelet Agents
  • Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 640
A recent 2024 meta-analysis (PMID 38473840) confirms cilostazol's role in reducing atherosclerosis progression and improving HDL cholesterol beyond its antiplatelet and vasodilatory effects, suggesting additional pleiotropic actions on vascular biology.
This is a shared conversation. Sign in to Orris to start your own chat.